Scilex Discloses 193.75M Shares in Denali After Business Combination
Rhea-AI Filing Summary
Denali Capital Acquisition Corp. (SMNR) Form 3 reports initial beneficial ownership by Scilex-related entities following a business combination that closed under an amended merger agreement. Scilex, Inc. indirectly holds 193,750,000 shares of Denali Common Stock, Scilex Bio, Inc. holds 6,250,000 shares, and Scilex Holding Company directly holds 1,054,849 shares. The largest block reflects an exchange of Old Semnur shares into Denali Common Stock at an exchange ratio of 1.25 to 1. The filing documents share origins: exchanges from Series A Preferred, a pre-combination purchase, and conversion of a promissory note.
Positive
- Clear disclosure of share origins including the business combination exchange ratio of 1.25 to 1
- Substantial ownership by Scilex entities (193,750,000; 6,250,000; and 1,054,849 shares) is explicitly documented
Negative
- None.
Insights
TL;DR: Scilex entities now hold a substantial combined stake through the business combination, which materially concentrates ownership.
The Form 3 discloses that Scilex, Inc. indirectly controls 193.75 million shares and related entities control additional shares, creating a significant ownership position post-merger. The 1.25-to-1 exchange ratio explains the mechanics of the share conversion from Old Semnur into the Issuer. For investors, concentrated ownership can influence governance, strategic direction, and liquidity; the specifics here are clearly documented and allow modeling of potential voting power and dilution effects.
TL;DR: Large insider holdings and the described share exchanges are material for board control and corporate actions.
The filing shows Scilex Holding Company and its subsidiaries reporting director status and multi-hundred-million share positions originating from the business combination and related transactions (Series A Preferred exchange, prior purchase, and note conversion). This concentration is material to governance assessments because it affects control dynamics and the potential for related-party influence. The disclosure is straightforward and sufficient to evaluate ownership provenance but does not include downstream voting agreements or lock-ups.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents shares of the Common Stock of the Issuer (f/k/a Denali Capital Acquisition Corp. ("Denali")) received pursuant to a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, Denali Merger Sub, Inc., a wholly owned subsidiary of the Issuer, and the company formerly known as Semnur Pharmaceuticals, Inc. ("Old Semnur"). Upon consummation of the Business Combination, the reporting entities' shares of the common stock of Old Semnur were exchanged for the shares of Common Stock of the Issuer reported in this row, based on an exchange ratio of 1.25 to 1. Scilex, Inc. is the direct owner of the 193,750,000 shares of the Issuer's Common Stock set forth in this row. Scilex, Inc. is a subsidiary of Scilex Holding Company. Scilex Bio, Inc. is the direct owner of 6,250,000 shares set forth in this row. Scilex Bio, Inc. is a majority-owned subsidiary of Scilex Holding Company. Comprised of: (i) 542,361 shares of Common Stock issued pursuant to the Business Combination upon the exchange of 5,423,606 shares of Series A Preferred Stock of Old Semnur (each share of Series A Preferred Stock of Old Semnur was exchanged for one share of Series A Preferred Stock of the Issuer and 1/10th of a share of Common Stock of the Issuer), (ii) 500,000 shares of Common Stock purchased by Scilex Holding Company prior to the Business Combination, and (iii) 12,488 shares of Common Stock issued upon conversion of the Convertible Promissory Note previously issued by Denali Capital Acquisition Corp. to Scilex Holding Company, which was converted upon consummation of the Business Combination.
